Table of Contents

company-logo

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Homology Medicines Dividend Announcement

• Homology Medicines announced a annually dividend of $0.00 per ordinary share which will be made payable on . Ex dividend date: 2022-03-15
• Homology Medicines's trailing twelve-month (TTM) dividend yield is -%

Homology Medicines Dividend History

Ex-Div dateDividend amountDividend typePay date
2022-03-15$0.00annually

Homology Medicines Dividend per year

Homology Medicines Dividend Yield

Homology Medicines current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Homology Medicines stock? Use our calculator to estimate your expected dividend yield:

Homology Medicines Financial Ratios

P/E ratio-8.34
PEG ratio-0.41
P/B ratio16.19
ROE-106.82%
Payout ratio0.00%
Current ratio6.49
Quick ratio6.49
Cash Ratio5.68

Homology Medicines Dividend FAQ

Does Homology Medicines stock pay dividends?
Homology Medicines does not currently pay dividends to its shareholders.
Has Homology Medicines ever paid a dividend?
No, Homology Medicines has no a history of paying dividends to its shareholders. Homology Medicines is not known for its dividend payments.
Why doesn't Homology Medicines pay dividends?
There are several potential reasons why Homology Medicines would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Homology Medicines ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Homology Medicines has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Homology Medicines a dividend aristocrat?
Homology Medicines is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Homology Medicines a dividend king?
Homology Medicines is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Homology Medicines a dividend stock?
No, Homology Medicines is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Homology Medicines stocks?
To buy Homology Medicines you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Homology Medicines stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.